Quick Answer
COGNITION THERAPEUTICS INC reported Operating Income Loss of -$47.80 million for the year ending 2025.
- COGNITION THERAPEUTICS INC showed an increase of +11.4% in Operating Income Loss from 2024 to 2025.
- This data is from COGNITION THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$4.46 million | Q1 2021: -$5.58 million | Q2 2021: -$5.98 million | Q3 2021: -$5.22 million | Q1 2022: -$9.41 million | Q2 2022: -$12.21 million | Q3 2022: -$12.63 million | Q1 2023: -$8.97 million | Q2 2023: -$11.82 million | Q3 2023: -$14.75 million | Q1 2024: -$14.10 million | Q2 2024: -$14.68 million | Q3 2024: -$14.46 million | Q1 2025: -$13.78 million | Q2 2025: -$13.98 million | Q3 2025: -$6.38 million.
- Over the full 6 years of available data (2020 to 2025), COGNITION THERAPEUTICS INC's Operating Income Loss has declined by 174.6%.
- Historical annual values: Fiscal year 2025: -$47.80 million | Fiscal year 2024: -$53.97 million | Fiscal year 2023: -$50.72 million | Fiscal year 2022: -$43.55 million | Fiscal year 2021: -$28.60 million | Fiscal year 2020: -$17.41 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: